Fundraising Fox

Personal Genome Diagnostics

Baltimore, US · Founded 1901 · 63 employees on LinkedIn · 6 known investors

Find your way into Personal Genome Diagnostics

996 people in our graph share verified history with the Personal Genome Diagnostics team — schools, employers, funds. One of them is your warm intro.

Paul Kwanunlockedknows Victor Velculescu · together at Stanford University (overlapped)
×5knows the team · via Stanford University
×5knows the team · via Cornell
knows the team · via University of Rhode Island

A precision oncology company providing genomic testing and resources to support cancer care decisions, operating under Labcorp Oncology.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

Personal Genome Diagnostics was founded in 1901 by Victor Velculescu, Luis A. Diaz, Jr., Sam Angiuoli, and Sian Jones.

VVVictor Velculescu
Victor VelculescuinCo-founderVictor Velculescu is a Professor of Cancer Genetics and Epigenetics at Johns Hopkins University School of Medicine and Co-Director of Cancer Genetics and Epigenetics at the Sidney Kimmel Comprehensive Cancer Center, with research expertise in cancer genomics and liquid biopsy technologies that has contributed to FDA-approved diagnostic and therapeutic platforms. He is a founder of DELFI Diagnostics and Artemyx, and a member of the US National Academy of Medicine and National Academy of Inventors.
LA
Luis A. Diaz, Jr.Co-founder
SASam Angiuoli
Sam AngiuoliinCo-founder · Chief Information Officer2014–2022Sam Angiuoli is an executive officer at Personal Genome Diagnostics, a precision oncology company providing genomic testing to support cancer care decisions. He has over two decades of experience in developing technology for scientific and medical applications.
SJSian Jones
Sian JonesinCo-founder · VP of Genome Sciences2014–2020Sian Jones leads Personal Genome Diagnostics, a precision oncology company providing genomic testing under Labcorp Oncology. Jones has prior experience in research and development and clinical diagnostics in biotechnology, with expertise in cancer genetics, genomics, liquid biopsy, and tissue-based diagnostic approaches.
LK
Lisa KanninVP, Laboratory Operations2014–2017Lisa Kann is an Executive Officer at Personal Genome Diagnostics, a precision oncology company providing genomic testing under Labcorp Oncology. She has expertise in genomics applications, biomarker assay development for oncology, and CLIA-regulated laboratory operations.
AN
Anthony NewtonExecutive
WJWilliam J Stevens
William J StevensinChief Financial Officer2010–2019William J Stevens served as Chief Financial Officer for 11 years and now leads Personal Genome Diagnostics, a precision oncology company providing genomic testing and resources to support cancer care decisions.
MS
Mark SauseninVice President, Technology Innovation2021–2022
CCCindy Caccuro
Cindy CaccuroinVice President of Sales- Enterprise Solutions2015–2018
JBJeff Boschwitz
Jeff BoschwitzinChief Operating Officer2014–2016Jeff Boschwitz is an executive with experience in healthcare management consulting, diagnostic services, medical devices, and drug development. He has worked across multiple healthcare business areas with focus on precision medicine and cost-effective health outcomes.

Board

FD
Felix DawsonBoard director

Investors · 6

3B Future Health FundMonaco · $12M
Catalio Capital Management, LPNew York
Co-Win VenturesSuzhou
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
Windham Capital PartnersNew York · $1M – $5M
Vensana Capitalreported · 2 sourcesMinneapolis

Funding

SEC filings, press & company announcements

$197.6M disclosed across 7 of 8 rounds · 2014–2025

▶$97.7MraisedFeb 2021 · 38 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Luis A. Diaz, Jr.Director
  • Victor VelculescuDirector
  • Justin KleinDirector
  • Megan BaileyExecutive Officer, Director
  • Kavita PatelDirector
  • James LaFranceDirector
  • Scott GotshallExecutive Officer
  • Samuel AnguioliExecutive Officer
  • Lily LiDirector
  • Jack CrowleyExecutive Officer
  • Kevin ReidyDirector
Offering amount
$98.3M
Amount sold
$97.7M
First sale
Feb 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.8MraisedMay 2020 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Luis A. Diaz, Jr.Director
  • Garry NicholsonDirector
  • James LaFranceDirector
  • Jack CrowleyExecutive Officer
  • Megan BaileyExecutive Officer
  • Victor VelculescuDirector
  • Justin KleinDirector
  • Sam AnguioliExecutive Officer
  • Jason FullerDirector
  • Kavita PatelDirector
Offering amount
$3.5M
Amount sold
$2.8M
First sale
May 2020
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedJun 2019 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Luis A. Diaz, Jr.Director
  • Jason FullerDirector
  • Kavita PatelDirector
  • Sam AnguioliExecutive Officer
  • James LaFranceDirector
  • Garry NicholsonDirector
  • Jack CrowleyDirector
  • Victor VelculescuDirector
  • Justin KleinDirector
  • Douglas WardExecutive Officer, Director
Offering amount
$20M
Amount sold
$5M
First sale
Jun 2019
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$65.4MraisedOct 2017 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William StevensExecutive Officer
  • Douglas WardExecutive Officer, Director
  • Sam AnguioliExecutive Officer
  • James LaFranceDirector
  • Victor VelculescuDirector
  • Justin KleinDirector
  • Luis A. Diaz, Jr.Director
Offering amount
$111.5M
Amount sold
$65.4M
First sale
Oct 2017
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20.5MraisedNov 2015 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sam AnguioliExecutive Officer
  • William StevensExecutive Officer
  • Jeff BoschwitzExecutive Officer
  • Anthony NewtonExecutive Officer
  • Luis A. Diaz, Jr.Executive Officer, Director
  • Justin KleinDirector
  • Victor VelculescuExecutive Officer, Director
Offering amount
$21.4M
Amount sold
$20.5M
First sale
Oct 2015
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.3MraisedJun 2015 · 18 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Victor VelculescuExecutive Officer, Director, Promoter
  • Luis A. Diaz, Jr.Executive Officer, Director, Promoter
  • Lisa KannExecutive Officer
  • Sam AngiuoliExecutive Officer
  • Felix DawsonDirector
  • Anthony NewtonExecutive Officer
  • William J StevensExecutive Officer
  • Sian JonesExecutive Officer
  • Mark SausenExecutive Officer
  • Cindy CaccuroExecutive Officer
  • Jeff BoschwitzExecutive Officer
Amount sold
$4.3M
Sales commissions
$250K
Proceeds to insiders
$200K
Placement agents
Pickwick Capital Partners, LLC
First sale
May 2015
Incorporated
Corporation, Maryland, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedMar 2014 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Victor VelculescuExecutive Officer, Director, Promoter
  • Luis A. Diaz, Jr.Executive Officer, Director, Promoter
  • Kenneth W. KinzlerPromoter
  • Anthony NewtonExecutive Officer
  • William J. StevensExecutive Officer
  • Bert VogelsteinPromoter
Offering amount
$3.5M
Amount sold
$2M
Minimum investment
$100K
Sales commissions
$57.5K
Proceeds to insiders
$150K
Placement agents
Pickwick Capital Partners, LLC
First sale
Mar 2014
Incorporated
Corporation, Maryland, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2017$297.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2016$223K
National Institutes of Health (NIH)National Institutes of HealthPhase I2015$216.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2015$214.4K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Personal Genome Diagnostics Raises $75 Million in Series B | Chief Healthcare Executivechiefhealthcareexecutive.com · Nov 202510 Innovations in 10 Years: Personal Genome Diagnostics (PGDx) - Johns Hopkins Technology Venturesventures.jhu.edu · Feb 2025Personal Genome Diagnostics Raises $103M in Series C Financing | GenomeWebgenomeweb.com · Feb 2021PGDx looks to raise $3.5M following FDA clearance for cancer diagnostics tech - Baltimore Business Journalbizjournals.com · May 2020Personal Genome Diagnostics Raises $75 Million to Bring Regulated IVD Genomic Tests to Cancer Patients Worldwideprnewswire.com · Jan 2018Personal Genome Diagnostics raises $21.4M Series Atechnical.ly · Oct 2015

Frequently asked questions

What does Personal Genome Diagnostics do?
A precision oncology company providing genomic testing and resources to support cancer care decisions, operating under Labcorp Oncology.
Who founded Personal Genome Diagnostics?
Personal Genome Diagnostics was founded by Victor Velculescu, Luis A. Diaz, Jr., Sam Angiuoli, Sian Jones in 1901.
Who are Personal Genome Diagnostics's investors?
Personal Genome Diagnostics's investors include 3B Future Health Fund, Catalio Capital Management, LP, Co-Win Ventures, New Enterprise Associates (NEA), Windham Capital Partners, Vensana Capital.
How much funding has Personal Genome Diagnostics raised?
Personal Genome Diagnostics has disclosed $197.6M raised across 7 of its 8 known rounds.
Where is Personal Genome Diagnostics headquartered?
Personal Genome Diagnostics is headquartered in Baltimore, US.